Hematology

FDA grants fast track designation for vaccine-enhanced adoptive T cell therapy for glioblastoma

The U.S. Food and Drug Administration (FDA) has granted fast track designation to a vaccine-enhanced adoptive T cell therapy (VACT) for treatment of glioblastoma multiforme, according to a press release. Phase 1 and 2a studies in multiple cancers, including glioblastoma, have demonstrated significant benefit when using TVAX Biomedical VACT. "We...